Barentz acquires Anshul Life Sciences to strengthen India portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Campaign launched to spread awareness regarding dengue prevention and control
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The inspections concluded with no Form 483 observations or significant critical findings
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Subscribe To Our Newsletter & Stay Updated